Table 2.
Core Gene Pathway Alterations and Association with Lymph Nodes Involvement
| Mutated pathway | KRASmut | KRASmut | KRASmut | KRASmut | KRASWT | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Overall, n=473 | Tumor size ≤ 2cm, n=84 | Tumor size (2, 3cm], n=211 | Tumor size > 3cm/T4, n=178 | Overall, n=40 | ||||||
| N1-2 | P | N1-2 | P | N1-2 | P | N1-2 | P | N1-2 | P | |
| TP53 | ||||||||||
| WT | 90/172 (52.3%) | 1 | 8/34 (23.5%) | 1 | 45/79 (57.0%) | 1 | 37/59 (62.7%) | 1 | 12/30 (25.0%) | 1 |
| Missense | 106/197 (53.8%) | 0.776† | 17/31 (54.8%) | 0.010† | 45/80 (56.3%) | 0.928† | 44/86 (51.2%) | 0.169† | 4/9 (40.4%) | 0.812‡ |
| Truncating | 46/93 (49.5%) | 0.656† | 5/18 (27.8%) | 0.736‡ | 23/46 (50.0%) | 0.451† | 18/29 (62.1%) | 0.953† | 1/1 | – |
| Others* | 6/11 (54.5%) | 0.886† | 1/1 | – | 4/6 | – | 1/4 | – | None | – |
| Mutated | 158/301 (52.5%) | 0.972† | 23/50 (46.0%) | 0.036† | 72/132 (54.5%) | 0.732† | 63/119 (52.9%) | 0.216† | 5/10 (50.0%) | 0.580‡ |
| Cell cycle | ||||||||||
| WT | 202/387 (52.2%) | 1 | 25/72 (34.7%) | 1 | 92/170 (54.1%) | 1 | 85/145 (58.6%) | 1 | 15/37 (40.5%) | 1 |
| Mutated | 46/86 (53.5%) | 0.828† | 6/12 (50.0%) | 0.310‡ | 25/41 (61.0%) | 0.428† | 15/33 (45.5%) | 0.169† | 2/3 (66.7%) | 0.565‡ |
| TGFb | ||||||||||
| WT | 195/374 (52.1%) | 1 | 26/72 (36.1%) | 1 | 94/170 (55.3%) | 1 | 75/132 (56.8%) | 1 | 15/34 (44.1%) | 1 |
| Mutated | 53/99 (53.5%) | 0.805† | 5/12 (41.7%) | 0.712‡ | 23/41 (56.1%) | 0.926† | 25/46 (54.3%) | 0.771† | 2/6 (33.3%) | 1.000‡ |
| Mutated pathways | ||||||||||
| 0-1 | 180/344 (52.3%) | 1 | 22/68 (32.4%) | 1 | 84/152 (55.3%) | 1 | 74/124 (59.7%) | 1 | 16/35 (45.7%) | 1 |
| 2-3** | 68/129 (52.7%) | 0.940† | 9/16 (56.3%) | 0.075† | 33/59 (55.9%) | 0.930† | 26/54 (48.1%) | 0.154† | 1/5 (20.0%) | 0.373‡ |
| Trithorax | ||||||||||
| WT | 202/374 (54.0%) | 1 | 27/75 (36.0%) | 1 | 100/166 (60.2%) | 1 | 75/133 (56.4%) | 1 | 10/29 (34.5%) | 1 |
| Mutated | 46/99 (46.5%) | 0.181† | 4/9 (44.4%) | 0.620‡ | 17/45 (37.8%) | 0.007† | 25/45 (55.6%) | 0.922† | 7/11 (63.6%) | 0.096‡ |
| WNT | ||||||||||
| WT | 232/430 (54.0%) | 1 | 31/78 (39.7%) | 1 | 106/187 (56.7%) | 1 | 95/165 (57.6%) | 1 | 17/38 (44.7%) | 1 |
| Mutated | 16/43 (37.2%) | 0.036† | 0/6 | – | 11/24 (45.8%) | 0.314† | 5/13 (38.5%) | 0.181† | 0/2 | – |
| Hedgehog | ||||||||||
| WT | 246/461 (53.4%) | 1 | 31/81 (38.3%) | 1 | 116/204 (56.9%) | 1 | 99/176 (56.3%) | 1 | 16/37 (43.2%) | 1 |
| Mutated | 2/12 (16.7%) | 0.012† | 0/3 | – | 1/7 (14.3%) | 0.046‡ | 1/2 (50.0%) | 1.000‡ | 1/3 (33.3%) | 1.000‡ |
*Other mutation subtypes included mixed cases, in-frame insertion or deletion and silent mutation
**Alterations of 2-3 pathways among TP53, cell cycle pathway and TGFb pathway; †Chi-squared test; ‡Fisher exact test